Embecta Corp (NASDAQ:EMBC) stock rose 10.11% (As on November 28, 6:13:24 AM UTC-4, Source: Google Finance) after the company received an upgrade from Neutral to Buy by BTIG, with a new price target of $26.00. The decision followed a significant ~30% increase in Embecta’s share value on Tuesday, as the market responded positively to the company’s announcement to halt its patch pump program.
The analyst from BTIG expressed approval of the company’s strategic move, highlighting the financial benefits, including an improvement in adjusted EBIT margin due to a substantial reduction in R&D expenses. This change is expected to bolster Embecta’s free cash flow, enabling the company to decrease its net leverage ratio to approximately 3x by the end of the fiscal year 2025. Embecta’s financial strategy also involves lowering separation-related expenses, anticipated to be between $50 million and $60 million in FY25, down from $165 million in FY24. The analyst noted this could provide Embecta with the flexibility to engage in more strategic mergers and acquisitions that align with its core competencies, as indicated by the company’s management. The upgrade reflects confidence in Embecta’s ability to navigate industry challenges, including those from pumps and GLP-1s, which have resulted in an approximate 1% revenue compound annual growth rate since the company’s spin-off. The firm’s strong financial performance is characterized by consistent quarters of exceeding expectations and raising future projections.
BTIG’s valuation of Embecta at a price target of $26 is based on 9 times the firm’s estimated earnings per share over the next 12 to 24 months. The analyst justifies the multiple, which remains below the average for Medical Supplies peers, by balancing Embecta’s relatively flat revenue projections against its superior margin profile compared to competitors.
Meanwhile, the company’s revenues increased by $4.2 million, or 1.5%, to $286.1 million for the fourth quarter of 2024 as compared to revenues of $281.9 million for the fourth quarter of 2023. Changes in the revenues are driven by the volume of goods that we sell, the prices we negotiate with customers and changes in foreign exchange rates. The increase in revenues was driven by $13.7 associated with favorable changes in price and a $2.3 increase in contract manufacturing revenues related to sales of non-diabetes products to BD. The Company expects the restructuring plan to be substantially complete during the first half of fiscal year 2025 and expects the discontinuation of the patch pump program and organizational restructuring plan to generate annualized pre-tax cost savings of between $60 million and $65 million.